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The identiﬁcation of recent HIV infection is important for epidemiological studies and to
monitor the epidemic. The objective of this study was to evaluate two rapid tests that are
easily available to the Brazilian scientiﬁc community for using as markers of recent HIV
infection. The Rapid Test – HIV-1/2 Bio-Manguinhos (Bio-Manguinhos/Fiocruz, Brazil) and
the Rapid Check HIV 1&2 (NDI-UFES, Center for Infectious Diseases, Universidade Federal
do Espírito Santo) were tested, using 489 samples with HIV positive serology, from blood
donors, previously classiﬁed as recent or long-term infection by serological testing algorithm
for recent HIV seroconversion (STARHS) or LS-HIV Vitros assay methods. The samples were
diluted prior to testing (1:50 and 1:100 for the Rapid Test – HIV-1/2 Bio-Manguinhos, and 1:500
and 1:600 for the Rapid Check HIV 1&2). Negative samples were considered recent infection,
whereas those showing any color intensity were associated with long-term infection. Thebest dilutions were 1:100 for HIV-1/2 Bio-Manguinhos test (Kappa = 0.840; overall agreement
= 0.93), and 1:500 for the Rapid Check HIV 1&2 (Kappa = 0.867; overall agreement = 0.94). The
results suggest that both rapid tests can be used to detect recent seroconversion.
(AIDS)-related deaths, the number of people living with HIVIntroductionDespite the great progress achieved in preventing new human
immunodeﬁciency virus (HIV) infections and the reduction of
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the annual number of acquired immunodeﬁciency syndrome-000, São Paulo, SP, Brazil.
continues to grow worldwide. In 2010, 34 million people were
estimated to be infected globally, a number 17% higher than in
2001, and the prevalence was nearly three times higher than
eserved.
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hat found in 1990. In the same period, there were 2.7 million
ewcases,whichmeansover 7,000newHIV infectionsper day,
nd 1.8 million annual deaths from AIDS.1 There is evidence
f success in HIV prevention in diverse settings, such as the
eduction on the annual rate of new HIV infections around the
lobe, as well as a lower prevalence of HIV among young peo-
le in several countries.2,3 Efforts to prevent HIV transmission
hould focus on recent infections, due to their greater impact
n the spread of the epidemic.
The identiﬁcation of populations at risk of HIV infection is
priority for public health and epidemiological surveillance.
n recent years, epidemiologists have used different laboratory
ests to estimate the incidence of HIV in certain populations,
r to check the number of new infections in a given period of
ime.4–7 These strategies are important tools to identify popu-
ationswith high rates of ongoing transmission, to understand
he patterns of transmission, to monitor and direct resources
nd prevention programs (especially in low-income countries,
here the concentration of cases is higher), and to assess the
uture of the HIV epidemic.8–11
Likewise, for studies that identify subtypes of HIV-1 or
atterns of drug resistance in infected individuals, the identi-
cation of recent infected individuals can provide important
nformation about the dynamics of the epidemic.12–14
Detection of early infection can also be of clinical signiﬁ-
ance to the infected individual. The identiﬁcation of people
t an early stage of infection may accelerate the onset of
reatment, improving long-term prognosis. Early treatment,
long with appropriate counseling and partner notiﬁcation,
an help reduce secondary transmission by the newly infected
artners.15–17
The determination of incidence from conventional epi-
emiological methods is complex and expensive. The
evelopment of tools that could indicatewhether apersonwas
nfected recently has always been a priority for HIV research.
n 1998, Janssen et al.18 described the serological testing algo-
ithm for recent seroconversion (STARHS) to estimate the
ncidence of HIV-1 in different populations. The technique
as based on the principle that antibody titers against HIV
ncrease gradually over the initial months after seroconver-
ion. Themethodwas based on enzyme immunoassays (ELISA
enzyme-linked immunoabsorbent assay) of the ﬁrst gener-
tion (Abbott, and later manufactured by Organon Teknika).
ubsequently, studies have shown that this technology could
howunspeciﬁc recent infection results amongwith otherHIV
ubtypes, since the test is based on HIV-1 subtypes B antigen.
nother problem is that the companies discontinued the ﬁrst
eneration tests. In 2002, Parekh et al.19 developed a new IgG
apture enzyme immunoassay (BED-EIA), which is based on
he detection of gradual increase in the proportion of HIV-
peciﬁc IgG 1 and total IgG after seroconversion. This test
howed a similar sensitivity to detect speciﬁc antibodies to
he various HIV-1 subtypes. These methods can differentiate
ndividuals with recent seroconversion from long-term infec-
ion within about six months after seroconversion, and can
stimate HIV incidence using a single cross-sectional study.20owever, false positive results also occurred among long-
erm infection. Factors such as heterogeneity of the immune
esponse to HIV-1 genotype and use of antiretroviral therapy
ay cause misclassiﬁcation. Thus, these assays are used at a2;16(5):452–456 453
population level, and should not be used as a diagnostic tool,
since theymay bemisleading for the individual case deﬁnition
of recent infection.
Another limiting factor for their use was the need for spe-
cial equipment to perform the immunoassays, and the many
hours required to obtain the results.21,22 In places with limited
resources, where the majority of diagnostic tests are per-
formed using HIV rapid tests, these disadvantages may be of
concern, and for those reasons, it is necessary to develop and
validate simple tests that can be used continuously, regardless
of any commercial source.21
The development of simple, rapid tests with high sensitiv-
ity and speciﬁcity was a major breakthrough in the diagnosis
of HIV infection. These tests provide results in a very short
time (minutes), do not require special laboratory equipment,
and are, in addition, very economical, having beenwidely used
as diagnostic methods, particularly in regions with limited
resources and high prevalence of HIV infection.23–25 The avail-
ability of a rapid test that also has the ability to accurately
determine the incidence would be a useful epidemiological
tool to assess the HIV epidemic in these regions.25,26
Recently, some researchers8,27,28 evaluated the use of rapid
tests for the diagnosis of recent infection. The aim of the
present study was to evaluate rapid tests manufactured in
Brazil for this purpose.
Materials and methods
Two HIV rapid tests (RT) were analyzed: Rapid Test - HIV-1/2
Bio-Manguinhos (Bio-Manguinhos/Fiocruz, Brazil) and Rapid
Check HIV 1&2 (NDI-UFES, Center for Infectious Diseases, Uni-
versidade Federal do Espírito Santo). Both tests are provided
solely by the Ministry of Health, and are not commercialized.
These assays consist of speciﬁc HIV-1/2 antigens adsorbed on
special membranes. The results can be visualized in the form
of bands on the membranes. For the purposes of the present
research, theoriginal assaysweremodiﬁedexclusively bydilu-
tion of samples, and the reagents and materials were not
changed.
A total of 489 HIV-positive serum samples from the Epi-
demiology Recipient and Donor Evaluation Study (REDS)29
were used for this evaluation. Of these, 147, 155, and 187 were
fromblooddonations of the years 2007, 2008, and 2009, respec-
tively. Samples from 2007 had previously been evaluated by
the STARHS method (Vironostika HIV-1 microElisa System;
bioMérieux – Raleigh, NC, USA), while in the 2008 and 2009
samples, the LS-HIV Vitros Assay method (Ortho Diagnostics,
Raritan, NJ) was utilized.30 The results obtained during the
REDS were used to classify the samples as a recent or long-
term infection.
First, four samples classiﬁed as recent infection and four
samples classiﬁed as long-term infection were selected to
onset of standardization. Serial dilutions were made from 1:10
to 1:10,000 in negative human serum. From this preliminary
test, the best two dilutions were selected to evaluate a large
number of samples. Since these are tests whose results are
obtained by colorimetric bands, the reading was visual, on a
properly lit and ﬂat surface. Non-reactive samples after dilu-
tion, that is, with no band at the location indicated by the
454 braz j infect d i s . 2012;16(5):452–456
Table 1 – Comparison of different rapid test dilutions and the reference ELISA tests (STAHRS and LS-HIV).
Reference ELISA
Long-term Recent Total
HIV 1/2 Bio-Manguinhos
1:50
Long-term 330 (96.2%) 13 (3.8%) 343
Recent 35 (24%) 111 (76%) 146
1:100
Long-term 324 (94.5%) 19 (5.5%) 343
Recent 14 (9.6%) 132 (90.4%) 146
Rapid Check HIV 1 & 2
1:500
Long-term 327 (95.9%) 14 (4.1%) 341
Recent 13 (9%) 132 (91%) 145
1:600
Long-term 316 (92.7%) 25 (7.3%) 341
Recent 7 (4.8%) 138 (95.2%) 145
HIV-1/2 Bio-Manguinhos 1:50 – Kappa coefﬁcient = 0.755; Overall agreement = 0.90.
HIV-1/2 Bio-Manguinhos 1:100 – Kappa coefﬁcient = 0.840; Overall agreement = 0.93.
ent
entRapid Check HIV 1&2 1:500 – Kappa coefﬁcient = 0.867; Overall agreem
Rapid Check HIV 1&2 1:600 – Kappa coefﬁcient = 0.848; Overall agreem
colorimetric test, were associated with cases of recent infec-
tion; those that had any staining intensity at the location
indicated were associated with long-term infections.
For the Rapid Test - HIV-1/2 Bio-Manguinhos, the 1:50 and
1:100 dilutions were evaluated, as both had similar results to
the samples tested. Samples were diluted in plasma and 5L
of the ﬁnal dilution was used for testing.
For the Rapid CheckHIV 1&2 assay, the 1:500 and 1:600 dilu-
tions were used. Samples were diluted in negative plasma and
10L were used for testing.
Apart from the dilutions, the tests were performed accord-
ing to the manufacturer’s instructions.
Statistical analysis was performed using the kappa coef-
ﬁcient, which assesses the agreement beyond chance of the
results with the reference methods (STARHS and LS-HIV Vit-
ros assay). The sensitivity and speciﬁcity of each assay were
determined with a conﬁdence interval of 95%.Results
Table 1 shows the test results obtained by the HIV-1/2 Bio-
Manguinhos using the best two dilutions (1:50 and 1:100), and
Table 2 – Comparison of sensitivity, speciﬁcity, kappa coefﬁcien
negative predictive value (NPV) of tests at their best dilutions.
Parameters (95%CI) Bio-Manguinhos x STARHS
n = 147
Bio-Manguinho
n = 34
Sensitivity 0.9889 (0.9396-0.9997) 0.8972 (0.8531-0
Speciﬁcity 0.8772 (0.7632-0.9492) 0.9213 (0.8446-0
Kappa coefﬁcient 0.8831 (0.8047-0.9616) 0.7656 (0.6906-0
Overall agreement 0.9456 (0.8956-0.9762) 0.9035 (0.8672-0
PPV 0.9671 (0.8555-0.9702) 0.9701 (0.9393-0
NVP 0.9804 (0.8955-0.9995) 0.7593 (0.6675-0
Rapid test HIV-1/2 Bio-Manguinhos in 1:100 dilution; Rapid Check HIV 1 &= 0.94.
= 0.93.
the tests results by the Rapid Check HIV 1&2 at dilutions 1:500
and 1:600. Of the 146 samples deﬁned as recent infection by
reference ELISA, 111 (76%) and 132 (90.4%) were considered
to be new infection by HIV-1/2 Bio-Manguinhos at dilutions
of 1:50 and 1:100, respectively. Of the 343 long-term infection
samples, 330 (96.2%) and 324 (94.5%) were considered to be
long-term by the HIV-1/2 Bio-Manguinhos in 1:50 and 1:100
dilutions, respectively. Therefore, the 1:100 dilution was cho-
sen for this test. For the test Rapid Check HIV 1&2, of 145
samples deﬁned as recent infection by reference ELISAs, 132
(91%) were considered recent infection at a dilution of 1:500,
and 138 (95.2%) at a dilution of 1:600. Of the 341 samples
deﬁned as long-term, Rapid Check detected 327 (95.9%) when
at a dilution of 1:500, and 316 (92.7%) at a dilution of 1:600.
Table 2 summarizes the results obtained by comparing
each test with each reference ELISA. The overall concordance
was similar, ranging from 0.90 to 0.95.Discussion
RTs are a practical and economical method for the diagno-
sis of recent HIV infection. Especially in places with limited
t, overall agreement, positive predictive value (PPV), and
s x LS-HIV
2
Rapid Check x
STARHS*n = 145
Rapid Check x LS-HIV
n = 341
.9318) 0.9775 (0.9212-0.9973) 0.9524 (0.9183-0.9752)
.9678) 0.8571 (0.7378-0.9362) 0.9438 (0.8737-0.9815)
.8407) 0.8516 (0.7632-0.9399) 0.8740 (0.8157-0.9322)
.9326) 0.9310 (0.8768-0.9664) 0.9501 (0.9214-0.9707)
.9879) 0.9158 (0.8408-0.9629) 0.9796 (0.9530-0.9933)
.8363) 0.9600 (0.8629-0.9951) 0.8750 (0.7918-0.9337)
2 in 1:500 dilution.
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recent HIV-1 infection by a line immunoassay for HIV 1/2
conﬁrmation. Plos Medicine. 2007;4:1921–30.braz j infect d i s .
esources, to estimate HIV incidence, using an RT could be an
mportant tool for guiding prevention programs, identifying
opulations with high transmission rates, as well as under-
tanding the patterns of transmission.
Incidence calculation by prospective cohort studies is
xpensive, and generally the samples are non-representative
f the general population. Mathematical models created for
hese estimations are based on epidemiological data on HIV
revalence, diagnosis of AIDS, or death rates. However, they
re difﬁcult to standardize or require complex statistical
ethods.6 Because of this complexity and the limitations of
ethods to estimate HIV incidence, different laboratory tech-
iques have been developed, seeking to distinguish recent
nfections from long-term infections.7,11,18,19,21,27,28,31–44 These
ests, however, depend on the calibration panels, which
re not always available in a given country. In the cur-
ent study, techniques that are easily accessed by the
razilian scientiﬁc community and public services were
valuated in order to facilitate the development of epi-
emiological studies needed to detect incident cases of HIV
nfection.
The results suggest that, by modifying the sample dilution,
IV-1/2 RTs had a similar performance as the reference ELISAs
STARHS and LS-HIV Vitros assay) to discriminate between
ecent and long-term infection.
The overall agreement between the RTs and the refer-
nce tests was 93% on average. As these tests are visually
nterpreted, it was not possible to calculate the coefﬁcient of
ariation.
In 2005, Soroka et al.28 modiﬁed three protocols for
he detection of recent seroconversion by RT. Determine
IV-1/2 (Abbott Laboratories), OraQuick Advance HIV-1/2
OraSure Technologies), and SeroStrip HIV-1/2 (Chem-Bio)
ere used, and obtained a general agreement of 95% for
he tested samples. More recently, Kshatriya et al.27 also
ompared Determine HIV-1/2 and OraQuick Advance HIV-
/2 tests, and showed an agreement of 97% and 93%,
espectively.
The samples used in the present study were previously
ested by the reference methods STARHS and LS-HIV Vit-
os assay.29 Similar results were observed with both assays.
owever, in 2011, Kassanjee45 suggested caution in the
se of LS-HIV Vitros Assay, since it has high false-recent
ates.
Unfortunately, the results of both tests were not available
or the same sample, thus it was not possible to determine the
greement between the two tests in the tested samples. In this
ense, the limitation of this study is the same as reported by
hemajority of other investigators seeking to standardize tests
or this purpose, that is, the lack of availability of speciﬁc sam-
les in anadequate volume thatwouldallow for the evaluation
f a test series, comparing performance among them.
Another limitation of this study is that the interval between
nfection and seroconversion could not be determined. The
TARHS and LS-HIV Vitros assay tests were standardized
or a window period of 170 days using samples with the
indow period previously known. The fact that this study’s
ethodology has shown good correlation with these meth-
ds does not necessarily imply that the window period is the
ame.
12;16(5):452–456 455
Conclusion
It is still premature to use this technology to deﬁne incidence.
However, it could be used to screen recently infected individ-
uals, who would need to be conﬁrmed by a follow up-sample,
or to be used in studies comparing the relative rate of newly
infected individuals in different populations.
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